Darrick Neibaur, DO
Ophthalmology · Henderson, NVNPI 1134375918
Payments from drug & device makers
Across 448 payments — averaging $79.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$14K
- Alcon$3K
- AbbVie$3K
- Bausch & Lomb Americas Inc.$2K
- Ivantis, Inc$2K
- Novartis$1K
- plus $10K from 29 others
What the payments were for
- Consulting fees$2,5537%
- Speaking & faculty fees$11,02831%
- Travel & lodging$3,74810%
- Food & beverage$17,67949%
- Education$800%
- Other$6602%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 54 | $14,293 |
| Alcon | 77 | $3,252 |
| AbbVie(2 entities) | 74 | $2,728 |
| Bausch & Lomb Americas Inc. | 38 | $2,230 |
| Ivantis, Inc | 23 | $1,566 |
| Novartis | 16 | $1,416 |
| Glaukos Corporation | 28 | $1,374 |
| Carl Zeiss Meditec USA, Inc. | 3 | $1,331 |
| Sight Sciences, Inc. | 11 | $871 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $863 |
| Rxsight Inc | 12 | $827 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $713 |
| Ocular Therapeutix, Inc. | 3 | $672 |
| Kala Pharmaceuticals, Inc. | 8 | $500 |
| NEW World Medical,inc. | 3 | $424 |
| Oyster Point Pharma, Inc. | 11 | $376 |
| ANI Pharmaceuticals, Inc. | 11 | $370 |
| Aerie Pharmaceuticals, Inc. | 7 | $315 |
| Ellexiscience | 1 | $286 |
| Tarsus Pharmaceuticals, Inc. | 9 | $248 |
| Microsurgical Technology, Inc. | 1 | $160 |
| Astellas Pharma US Inc | 2 | $142 |
| Apellis Pharmaceuticals, Inc. | 2 | $137 |
| Melinta Therapeutics, LLC | 1 | $124 |
| Mallinckrodt Hospital Products Inc. | 6 | $123 |
| Amgen(2 entities) | 6 | $102 |
| Eyevance Pharmaceuticals LLC | 1 | $85 |
| Dompe US, Inc. | 2 | $56 |
| Lensar, Inc. | 2 | $32 |
| Halozyme Inc | 2 | $28 |
| Genentech USA, Inc. | 1 | $26 |
| Harrow Eye, LLC | 1 | $23 |
| Eyepoint US, Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$13,249
- Hydrus Microstent$2,069
- XIIDRA$1,269
- CIRRUS HD-OCT$1,251
- CLARUS$1,251
- FORUM$1,251
- Humphrey HFA$1,251
- IOLMaster 700$1,251
- enVista Aspire IOL$1,097
- TENEO$1,097
- STELLARIS ELITE$1,097
- XEN GLAUCOMA TREATMENT SYSTEM$1,000
- Hydrus$673
- DEXTENZA$660
- Clareon$634
- OMNI(R) SURGICAL SYSTEM (US)$544
- RXSIGHT CONTACT LENS$426
- RXSIGHT INJECTOR CARTRIDGE$426
- RXSIGHT INJECTOR HANDPIECE$426
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$426
How this compares
$35,748 in reported general payments places this provider in the 80th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 205 | $282,567 |
| IlevroNepafenac | 232 | $85,049 |
| LumiganBimatoprost | 121 | $58,375 |
| XiidraLifitegrast | 33 | $51,152 |
| Prednisolone Acetate | 1,227 | $41,630 |
| RocklatanNetarsudil Mesylat/Latanoprost | 40 | $30,646 |
| ProlensaBromfenac Sodium | 80 | $27,952 |
| CombiganBrimonidine Tartrate/Timolol | 74 | $25,707 |
| TyrvayaVarenicline Tartrate | 27 | $17,623 |
| Lotemax SmLoteprednol Etabonate | 46 | $14,263 |
| Cyclosporine | 21 | $11,666 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $10,941 |
| Alphagan PBrimonidine Tartrate | 19 | $9,336 |
| Ofloxacin | 753 | $9,098 |
| Bromfenac Sodium | 46 | $8,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,728 | $375,985419 claims |
| NovartisIlevro | $1,416 | $85,049232 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $2,230 | $56,56747 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $713 | $42,216126 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $315 | $30,64640 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $376 | $17,62327 claims |
| AlconSimbrinza | $3,252 | $10,94136 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $14,293 | $6,52625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Henderson
- Judy LiuHenderson$632K
- Peter DebryHenderson$323K
- Rene ZamoraHenderson$216K
- Dan EisenbergHenderson$7K
- Rajy RouweyhaHenderson$3K
- Arshad KhananiReno$45.8M
- Eva LiangLas Vegas$2.2M
- Matthew SwanicLas Vegas$433K
- Nelson LopezLas Vegas$193K
- Kent WellishLas Vegas$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.